SCHEMBL22308912

SCHEMBL22308912

CC(O)c1c(N)ncnc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 2/20 0.54
▸ KIT P10721 2/20 0.51
▸ SMARCA2 P51531 1/20 0.46
▸ SMARCA4 P51532 1/20 0.46
▸ PBRM1 Q86U86 1/20 0.46
▸ ADK P55263 1/20 0.44
▸ PTPN11 Q06124 1/20 0.43
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CKS1B P61024 1/20 0.41
▸ SKP1 P63208 1/20 0.41
▸ SKP2 Q13309 1/20 0.41
▸ GPR119 Q8TDV5 5/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ PIK3CA P42336 1/20 0.39
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15728505 0.85 MAP4K4 (0.61) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL31737885 0.83 MAP4K4 (0.58) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL14782331 0.82 MAP4K4 (0.57) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL22308908 0.81 MAP4K4 (0.56) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL3882261 0.80 MAP4K4 (0.55) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL31737149 0.79 KIT (0.55) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL2795551 0.79 MAP4K4 (0.54) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL7660292 0.78 ALDH1A1 (0.56) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL3884725 0.77 MAP4K4 (0.53) MAP4K4KITSMARCA2SMARCA4PBRM1
SCHEMBL656985 0.77 HTT (0.60) MAP4K4KITSMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115485276-B Deuterated AKT kinase inhibitors 南京正大天晴制药有限公司 2024-05-31 — — CN disclosed
CN-117964620-A AKT inhibitors 南京正大天晴制药有限公司 2024-05-03 — — CN disclosed
CN-113272304-B AKT inhibitors 南京正大天晴制药有限公司 2024-03-29 — — CN disclosed
CN-115485276-A Deuterated AKT kinase inhibitors 南京正大天晴制药有限公司 2022-12-16 — — CN disclosed
US-20220144821-A1 AKT INHIBITOR NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) 2022-05-12 — — US disclosed
EP-3919491-A1 AKT INHIBITOR Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) 2021-12-08 — — EP disclosed
WO-2021228223-A1 DEUTERATED AKT KINASE INHIBITOR 南京正大天晴制药有限公司 2021-11-18 — — WO disclosed
CN-113272304-A AKT inhibitors 南京正大天晴制药有限公司 2021-08-17 — — CN disclosed
WO-2020156437-A1 AKT INHIBITOR 南京正大天晴制药有限公司 2020-08-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144821-A1 AKT INHIBITOR AKT2, AKT1, MTOR MAP4K4 194/4885KIT 1363/4885SMARCA2 3716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback